Wilma Zinke-Cerwenka

Antifungal Prophylaxis with Posaconazole Delayed-Release Tablet and Oral Suspension in a Real-Life Setting: Plasma Levels, Efficacy, and Tolerability

David Lenczuk, Wilma Zinke-Cerwenka, Hildegard Greinix et al. · Antimicrobial Agents and Chemotherapy · 2018 · 52 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Hepatic veno-occlusive disease in two patients with relapsed acute myeloid leukemia treated with anti-CD33 calicheamicin (CMA-676) immunoconjugate

Peter Neumeister, M. Eibl, Wilma Zinke-Cerwenka et al. · Annals of Hematology · 2001 · 50 citations

Medicine, Hematology, Oncology +16

Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT

Marie Robin, Raphaël Porcher, Wilma Zinke-Cerwenka et al. · Bone Marrow Transplantation · 2016 · 46 citations

Medicine, Hematology, Oncology +16

Megakaryocytic Morphology and Clinical Parameters in Essential Thrombocythemia, Polycythemia Vera, and Primary Myelofibrosis With and Without JAK2 V617F

Nataliya Vytrva, Elvira Stacher, Peter Regitnig et al. · Archives of Pathology & Laboratory Medicine · 2014 · 23 citations

Medicine, Hematology, Pathology +17

Accuracy of Whole‐Body¹⁸F‐FDP‐PET for Restaging Malignant Lymphoma

Peter Mikosch, H. J. Gallowitsch, Wilma Zinke-Cerwenka et al. · Acta Medica Austriaca · 2003 · 22 citations

Medicine, Nuclear Medicine, Oncology +12